British Journal of Cancer · 2004 · 52 citations · 39 references
MedicineMolecular BiologyOncologyMolecular OncologyNeoplasiaTumor ProgressionCancer GlycobiologyCancer Molecular PathologyCancer ProgressionLung CancerMalignant NeoplasmsMolecular Tumor ProfilingAberrant O-glycosylation In CancerImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingLung AdenocarcinomaMucin-type O-glycosylationO-glcnacylation In Cancer
Initial glycosylation of mucin-type O-linked protein is catalysed by one of the UDP-GalNAc: polypeptide N-acetyl-galactosaminyl transferase-3 (GalNAc-T3). O-glycosylation is important in the binding of cell adhesion molecules, cell differentiation, invasion, and metastasis in tumours. This study was designed to detect GalNAc-T3 expression in lung adenocarcinoma by using immunohistochemical staining, and to evaluate the relationship between the GalNAc-T3 expression level and prognosis and recurrence in completely resected lung adenocarcinoma patients. A low expression of GalNAc-T3 was detected in the cytoplasm of tumour cells in 79 of 148 patients (53.4%) with lung adenocarcinoma. The low expression of GalNAc-T3 was associated with poorly differentiated tumour (P<0.0001), poor pathologic stage (P<0.0001), lymph node metastasis (P<0.0001), and tumour recurrence (P=0.016). The lung carcinoma patients with low GalNAc-T3 expression had a poorer prognosis than those with high GalNAc-T3 expression, using both univariate and multivariate analyses (overall survival: P<0.0001 and P=0.011, respectively). In addition, multivariate analysis of the clinicopathological characteristics of stage I lung adenocarcinoma indicated that the low expression of GalNAc-T3 was a significant independent factor for predicting poor prognosis and early recurrence (P=0.006, rr=2.87 and P=0.019, rr=3.05, respectively). The low expression of GalNAc-T3 may be a useful marker for predicting poor prognosis and early recurrence in completely resected lung carcinoma patients, particularly patients with stage I diseases.
39
Revisions in the International System for Staging Lung Cancer
Clifton F. Mountain · CHEST Journal · 1997 · 4.6K citations
Pepijn Brocken, P.N.R. Dekhuijzen, Liesbeth Peters-Bax et al. · Respiration · 2013 · 4K citations · Full text